Drugs / BPDO-1603
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04229927 | Feb 2020 → Feb 2022 | Alzheimer disease | Hyundai Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-07-31 | Hyundai Pharmaceutical Co., LTD. | Regulatory 매체 hyundaipharm.co.kr ↗
또한 CNS(중추신경계) 약물분야에서는 새로운 치매복합신약인 ‘BPDO-1603’에 대한 다국가 3상 임상시험계획서를 지난 7월 16일 식품의약품안전처로부터 승인 받았다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-07-31 | Hyundai Pharmaceutical Co., LTD. | 매체 hyundaipharm.co.kr ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPDO-1603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04229927 ↗ |